Hepatitis E: What’s New?
Response to Antiviral Therapy Stool & serum HEV RNA at 12 weeks Subsequent Management Undetectable HEV RNA Detectable HEV RNA serum±stool Relapse Treatment failure Stop RBV SVR 12 Extend RBV 3m 1 Initiate 6m RBV 2 Follow Up 3 3m PEG-IFN?? 1.Abravanel F, et al. Clin Infect Dis 2015; 60:96. 2.Kamar N, et al. N Engl J Med 2014; 370:1111. 3.Kamar N, et al. Clin Infect Dis 2010; 50:e30
Response to Antiviral Therapy RBV Therapy ■ Up to 38% of treated patients do not how an SVR or even relapse. ■ RBV dose reductions/Mutation in the viral polymerase (G1634R). Peg-IFN alfa ■ Alternative treatment option if there is no contraindication. ■ Peg-IFN for 3-12 months led to sustained clearance of HEV-RNA in chronic HEV who underwent LT. ■ Cause significant adverse effects & organ rejection in transplant recipients.
- Page 2 and 3: HEPATITIS E: WHAT’S NEW? Naglaa Z
- Page 4 and 5: Known Facts: HEV ■ 20 million HEV
- Page 6 and 7: Geographical Distribution of HEV Eg
- Page 8 and 9: HEV Genotypes Four genotypes/24 sub
- Page 10 and 11: Modes of HEV Transmission Fecal-ora
- Page 12 and 13: Clinical Picture of HEV
- Page 14 and 15: Complications of Acute HEV Acute Li
- Page 16 and 17: Clinical Picture: Complications Acu
- Page 18 and 19: Chronic Hepatitis E Persistently el
- Page 20 and 21: Chronic Hepatitis E Other Immunosup
- Page 22 and 23: Diagnostic tests for HEV IgM anti-H
- Page 24 and 25: HEV Diagnosis Acute HEV Chronic HEV
- Page 26 and 27: Treatment of HEV Acute HEV Signific
- Page 28 and 29: Treatment of Chronic HEV Reduction
- Page 34 and 35: Treatment of HEV: Future Therapy
- Page 36 and 37: Randomized trial in China, 112,604
Response to Antiviral Therapy<br />
RBV Therapy<br />
■ Up to 38% of treated patients do not how an SVR or even relapse.<br />
■ RBV dose reductions/Mutation in the viral polymerase (G1634R).<br />
Peg-IFN alfa<br />
■ Alternative treatment option if there is no contraindication.<br />
■ Peg-IFN for 3-12 months led to sustained clearance of HEV-RNA in<br />
chronic HEV who underwent LT.<br />
■ Cause significant adverse effects & organ rejection in transplant recipients.
Change language